MeetingInsights Archive - Cancer Therapy Advisor

Archives: MeetingInsights

Practice-Changing Presentations in Renal Cell Carcinoma: Insights From ASCO® 2021

Disclosure Elizabeth Plimack, MD, reported affiliations with Bristol-Myers Squibb, Genentech/Roche, Janssen, Merck Sharp & Dohme, Flatiron, Seattle Genetics, Pfizer, AstraZeneca, Infinity Pharmaceuticals, MEI Pharma, Pfizer, and Astellas Pharma. References Choueiri TK, Tomczak P, Park SH, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: randomized, double-blind, phase III Keynote-564…